10 results about "Alfacalcidol" patented technology

The invention discloses an alfacalcidol emulsion and a preparation method thereof, the pH value of the alfacalcidol emulsion is 6.5-8.0, and each 1000 ml of the alfacalcidol emulsion comprises 1-30 g of alfacalcidol, 100-300 g of oil for injection, 6-20 g of a phospholipid emulsifier, 0-20 g of poloxamer 188, 20-30 g of an osmotic pressure regulator and a proper amount of water. The preparation method of the drug-loaded fat emulsion injection comprises the following steps: preparing an oil phase; preparing a water phase; preparing a primary emulsion; performing high-pressure homogenization; adjusting the pH value; and sterilizing and storing. The alfacalcidol serves as an oil-soluble substance, can be dissolved in small oil drops (emulsion particles) of the emulsion or on an interfacial film, and can keep stable physicochemical properties and enhance the slow release performance in the storage process under certain conditions, so that the drug effect time is prolonged.

The utility model provides a kind of for the illumination reaction device of alfacalcidol, including the liquid storage tank to be lighted, circulating pump and illumination reaction tank formed by pipeline connection circulation passway, wherein: illumination reaction tank center is provided with the LED light of cylindrical shape, and there are a plurality of upper and lower interval arrangement partition plates in periphery, and the serpentine reaction channel of upper and lower bending is formed between a plurality of partition plates.The utility model illumination reaction device can realize uniform stable illumination reaction by the design of illumination reaction tank and serpentine reaction channel, reduce the optical path of reaction liquid, improve alfacalcidol illumination reaction efficiency and product quality consistency, effectively overcome the technical defects of traditional equipment.

The application belongs to the technical field of pharmaceutical preparations, and discloses a soft capsule preparation containing alfacalcidol and a preparation method thereof. The soft capsule preparation comprises a soft capsule shell and content filled in the soft capsule shell, and the content is composed of a drug-containing oil phase and alfacalcidol sustained-release pellets dispersed in the oil phase. The drug-containing oil phase comprises immediate-release alfacalcidol dissolved in an oily base. The sustained-release pellets comprise a blank pellet core, a drug-loaded layer and a separation layer, and the separation layer comprises a combined coating material of Eudragit RS30D and Eudragit RL30D. After oral administration, the alfacalcidol in the oil phase is rapidly released to achieve immediate effect, and the alfacalcidol in the sustained-release pellets is slowly released to maintain the steady state of blood drug concentration. The soft capsule preparation of the application realizes the dual-phase drug release behavior of immediate release and sustained release in the same soft capsule, so that the blood drug concentration is smooth and controllable within 24 hours, the steady state of blood drug concentration is maintained, the frequency of drug administration is reduced, and the risk of side effects such as hypercalcemia is reduced.

The utility model provides an alfacalcidol chiral selection reaction endpoint judgment device which comprises a reaction device, a detection device and a peristaltic pump, the detection device comprises an optical rotation measurement test tube and a polarimeter, and the optical rotation measurement test tube is arranged between a light source and a probe of the polarimeter; an inlet and an outlet at two ends of the optical rotation measuring test tube are respectively inserted into reaction liquid in the reaction device through hoses, and peristaltic pumps are arranged on pipelines of the hoses. According to the reaction endpoint judgment device disclosed by the utility model, the reaction device is creatively and directly combined with the polarimeter, the reaction liquid in the reaction is directly and circularly communicated to the polarimeter by utilizing the detection device, and the optical rotation change condition of the reaction liquid is measured in real time through the polarimeter, so that whether the synthetic reaction reaches the endpoint or not is indirectly judged; the determination method is accurate, high in efficiency and suitable for industrial production.

1. The name of the design product: packaging box (alfacalcidol soft capsule). 2. The use of the design product: for product packaging. 3. The design points of the design product: in the combination of shape and pattern. 4. The picture or photo that best indicates the design points: front view.

This invention provides ACE2 expression inhibitors and their application in ACE2-mediated diseases. It uses human RXRα as a target protein for virtual drug screening and employs computer molecular docking technology to screen compounds with high affinity for the human RXRα receptor. Combined with cell experiments, it screens compounds that inhibit ACE2. The ACE2 expression inhibitors are at least one of ten drugs selected from ursolic acid, phlorizin, resveratrol, triamcinolone, budesonide, fluticasone propionate, vitamin D2, vitamin D3, calcitriol, and alfacalcidol. The ACE2 inhibitors screened by this invention can serve as targeted drugs for ACE2-mediated diseases, providing more drug options for the prevention or treatment of these diseases.

The present application relates to the field of new drug preparations, and specifically discloses a kind of alfacalcidol soft capsule composition and preparation method thereof, the alfacalcidol soft capsule composition is prepared from alfacalcidol content drug liquid and soft capsule shell, wherein the soft capsule content drug liquid includes alfacalcidol co-crystal, oily base, the soft capsule shell is made of gelatin, plasticizer, purified water and light shielding agent;The alfacalcidol soft capsule composition prepared by the present application has high stability, and improves the problems of low solubility of raw material, easy oxidation and poor water solubility, the preparation method of the alfacalcidol soft capsule composition is simple and easy to operate, low in cost, and easy to mass production.

The invention relates to the field of novel pharmaceutical preparations, and particularly discloses an alfacalcidol soft capsule composition and a preparation method thereof.The alfacalcidol soft capsule composition is prepared from alfacalcidol content liquid medicine and a soft capsule shell, the soft capsule content liquid medicine comprises alfacalcidol eutectic crystals and an oily matrix, and the oily matrix is a mixture of alfacalcidol eutectic crystals and the oily matrix. The soft capsule shell is prepared from gelatin, a plasticizer, purified water and an opacifying agent; the alfacalcidol soft capsule composition prepared by the invention has high stability, the problems of low solubility, easy oxidation and poor water solubility of raw material medicines are solved, and the preparation method of the alfacalcidol soft capsule composition is simple and easy to implement, low in cost and easy for large-scale production and preparation.

The invention belongs to the technical field of chemical synthesis of medicines, and discloses a novel process for producing an alfacalcidol raw material medicine, which comprises the following steps of: introducing a Lewis acid catalyst in a key addition reaction, obviously shortening the reaction time and inhibiting side reaction; a quenching mode of dilution dropwise adding and real-time pH and temperature monitoring is adopted to replace one-time adding of a quenching agent, so that product decomposition or polymerization caused by too high local concentration is avoided; an acetone-ethanol cosolvent system is combined with a programmed gradient cooling crystallization process, so that the freezing point of the solvent is reduced, and crystals with uniform particle size and good fluidity are obtained; and a microwave-vacuum combined drying technology is adopted, so that the drying efficiency is greatly improved, and the moisture absorption stability of the product is improved. The method has the advantages of high overall efficiency, stable product quality, significantly improved product purity and yield, and suitableness for industrial production.

The invention discloses alfacalcidol gel which is prepared from the following components in percentage by mass: 0.01 to 0.05 percent of alfacalcidol, 1 to 3 percent of nanocrystalline stabilizer, 3 to 8 percent of oil phase, 6 to 12 percent of emulsifier, 3 to 6 percent of co-emulsifier, 4 to 8 percent of gel matrix and the balance of purified water. The invention aims to solve the technical problems of low oral absorption rate and low curative effect stability of medicines.